肠道免疫的安全靶向载体:大肠杆菌Nissle1917

发布时间：2018-03-14 04:36

本文选题：大肠杆菌(Escherichia　切入点：coli)Nissle　出处：《微生物学报》2013年06期 　论文类型：期刊论文

【摘要】：长期以来,如何激发高效的肠道黏膜免疫应答来预防肠道感染始终是较为棘手的问题。本文旨在对大肠杆菌(Escherichia coli)Nissle 1917作为肠道黏膜免疫的安全靶向载体,调理胃肠道菌群紊乱、缓解溃疡性结肠炎以及利用益生菌固有特性或优化特性进行治疗的可能性等相关研究进展作一综述。大肠杆菌Nissle1917(EcN)是一株可口服的优良益生菌,也可作为生物载体活苗候选株,兼有较强的肠道局部定殖能力和无免疫原性的特性。该菌株还可以作为载体靶向递呈TAT—凋亡素融合蛋白治疗结肠直肠癌,并在研发靶向递呈防御素治疗溃疡性结肠炎和克罗恩病上具有重要的功能。其基因修饰株能够原位递呈特定的抗原分子,有效激发特异性的黏膜免疫应答。重组大肠杆菌Nissle-HA110-120具有体外表达特异性抗原的能力,但EcN菌体本身不会引起黏膜免疫应答,也不影响对自身抗原的外周免疫耐受。同时,EcN具有很好的安全性,尤其是因炎症导致肠道防御屏障破坏的时候,重组大肠杆菌Nissle-HA110-120在健康或患有急性结肠炎的小鼠体内都没有迁移、克隆扩增和激活特异性CD4+T淋巴细胞的作用。
[Abstract]:For a long time, how to stimulate the intestinal mucosal immune response, to prevent intestinal infection is always a thorny problem. This paper aims to Escherichia coli (Escherichia coli) Nissle 1917 as a security target intestinal mucosal immunity to the carrier, conditioning gastrointestinal flora disorder, relieve ulcerative colitis and the possibility of treatment research progress reviewed by probiotic characteristics or inherent characteristics. The optimization of Escherichia coli Nissle1917 (EcN) is an excellent oral probiotic strains, also can be used as a biological carrier vaccine candidate strains have strong local intestinal colonization and non immunogenic properties. This strain can also be used as a carrier for targeted delivery of a TAT apoptin fusion protein in the treatment of colon cancer, and research target presentation has the important function of defensins in treatment of ulcerative colitis and Crohn's disease. The genetic modification of plants In situ antigen specific molecules, effectively stimulate the mucosal immune response specific. Recombinant Escherichia coli Nissle-HA110-120 has in vitro expression ability of specific antigen, but EcN cell itself does not cause mucosal immune response, does not affect the peripheral immune tolerance to self antigens. At the same time, EcN has good safety, especially when the intestinal barrier damage caused by defensive inflammation in mice, recombinant Escherichia coli Nissle-HA110-120 in the health or suffering from acute colitis without migration, amplification and activation of specific CD4+T lymphocyte clone.

【作者单位】：扬州大学兽医学院禽类预防医学教育部重点实验室;
【基金】：国家自然科学基金(30571374,30771603,31072136,31270171) 江苏省属高校自然科学重大基础研究项目(08KJA230002) 江苏高校优势学科建设工程资助项目教育部创新团队科技部转基因生物新品种培育重大专项(2009ZX08006-004B)~~
【分类号】：R392

【相似文献】